Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bluejay Diagnostics ( (BJDX) ) has shared an update.
On February 17, 2026, Bluejay Diagnostics reported significant progress in its SYMON II multicenter IL-6 monitoring study for sepsis, having enrolled 545 patients toward a 750-patient target under approved IRB protocols. Management said the growing, diverse dataset should strengthen its regulatory case and reduce clinical execution risk as the program moves from enrollment to data analysis and regulatory engagement.
The company also detailed advances in manufacturing readiness, including completion of cartridge characterization for U.S. commercial production and antibody production sufficient for over 10 million test cartridges. Ongoing work on cartridge fabrication, validation, and material substitutions, alongside a parallel, no–single point of failure technology transfer strategy, positions Bluejay in early 2026 with reduced execution risk and greater focus on commercialization preparedness.
The most recent analyst rating on (BJDX) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Bluejay Diagnostics stock, see the BJDX Stock Forecast page.
Spark’s Take on BJDX Stock
According to Spark, TipRanks’ AI Analyst, BJDX is a Neutral.
The score is held down primarily by weak financial performance (no meaningful revenue, sizable losses, and sustained negative free cash flow) despite low debt. Technicals add only modest support with a short-term bounce but a longer-term downtrend. Corporate events are positive for operational progress, but long regulatory/financing timelines and a negative P/E keep overall risk elevated.
To see Spark’s full report on BJDX stock, click here.
More about Bluejay Diagnostics
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes with its Symphony System, a cost-effective, rapid near-patient testing platform for sepsis triage and monitoring disease progression. Its lead product candidate is an IL-6 test for sepsis, designed to deliver accurate results in about 20 minutes to aid earlier and better triage and treatment decisions, though the system has not yet received U.S. regulatory clearance.
Average Trading Volume: 68,178
Technical Sentiment Signal: Sell
Current Market Cap: $1.89M
For detailed information about BJDX stock, go to TipRanks’ Stock Analysis page.